Sunday 22 December 2024

The Pharma Letter Podcast — Episode 12 — Mastering the microbiome

Biotechnology
Simon Wentworth
9 March 2022
episode12-b

More on this story...

Biotechnology
Takeda leads Big Pharma in microbiome-targeting treatments
17 August 2021
Biotechnology
Third clinical program bought by AI-based microbiome specialist
27 April 2022
Biotechnology
Seres Therapeutics falls despite positive Phase III results with SER-109
24 May 2022
Biotechnology
MaaT Pharma partners with Skyepharma on microbiome production
9 February 2022


Companies featured in this story

More ones to watch >


Today's issue

The week in pharma: action, reaction and insight – week to December 20
Pharmaceutical
The week in pharma: action, reaction and insight – week to December 20
22 December 2024
Biotechnology
FDA approves Novo Nordisk’s Alhemo
22 December 2024
Pharmaceutical
Italfarmaco’s Duvyzat backed by MHRA
22 December 2024
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

FDA approves Novo Nordisk’s Alhemo
22 December 2024
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze